Omalizumab
- Generic Name
- Omalizumab
- Brand Names
- Xolair, Omlyclo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 242138-07-4
- Unique Ingredient Identifier
- 2P471X1Z11
- Background
Omalizumab, manufactured by Genentech, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids . Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated . In September 2018, a new prefil...
- Indication
This drug is an anti-IgE antibody indicated for:
- Associated Conditions
- Chronic Idiopathic Urticaria, Moderate Asthma, Severe Asthma
- Associated Therapies
- -
XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16246
- Registration Number
- NCT05157087
- Locations
- 🇺🇸
Novartis Investigational Site, East Hanover, New Jersey, United States
A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT05061524
- Locations
- 🇰🇷
Ajou University Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Sinchon-dong, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Gumi, Sungnamsi, Korea, Republic of
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 320
- Registration Number
- NCT04998604
- Locations
- 🇺🇸
Cedars Sinai Medical Center Site Number : 8400026, Los Angeles, California, United States
🇺🇸Northwell Health Site Number : 8400044, Great Neck, New York, United States
🇺🇸Cleveland Clinic Foundation Site Number : 8400029, Cleveland, Ohio, United States
Gastrointestinal STRING Test With Oral Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 13
- Registration Number
- NCT04943744
- Locations
- 🇺🇸
Sean N Parker Center for Allergy and Asthma Research at Stanford University, Palo Alto, California, United States
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 114
- Registration Number
- NCT04778137
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Molecular Endotypes of Chronic Idiopathic Urticaria
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 15
- Registration Number
- NCT04774315
- Locations
- 🇺🇸
University of Colorado Anschutz, Aurora, Colorado, United States
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- University of Newcastle, Australia
- Target Recruit Count
- 200
- Registration Number
- NCT04585997
- Locations
- 🇦🇺
John Hunter Hospital, New Lambton, New South Wales, Australia
The Efficacy of Preseasonal Omalizumab Treatment
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT04489121
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04195958
- Locations
- 🇺🇸
Swedish Health Services, Seattle, Washington, United States
🇺🇸Broward Research Center, Pembroke Pines, Florida, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Carsten Bindslev-Jensen
- Target Recruit Count
- 20
- Registration Number
- NCT04037176
- Locations
- 🇩🇰
Odense Research Center for Anaphylaxis, Allergy Center, Odense University Hospital, Odense C, Funen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.